WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: CVS Caremark adds Zepbound and Foundayo to formulary — Warptech Lab News

Storia in 9 fonti

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

Raccontata da

biopharmadive.com

morningstar.com

independent.co.uk

fiercepharma.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

qz.comStai leggendo3 mesi fa

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

Timeline cronologica

giovedì 28 maggio 2026·biopharmadive.com
CVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
giovedì 28 maggio 2026·nbcnews.com
CVS Caremark will cover Lilly’s weight loss drug Zepbound once again
The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.

3 mesi fa

CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.

Leggi questa versione → originale

nbcnews.com3 mesi fa

CVS Caremark will cover Lilly’s weight loss drug Zepbound once again

The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.

Leggi questa versione → originale

cnbc.com3 mesi fa

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Leggi questa versione → originale

biopharmadive.com3 mesi fa

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Leggi questa versione → originale

independent.co.uk3 mesi fa

CVS expands access to blockbuster weight-drugs in surprise reversal

This move marks a pivotal shift for patients seeking access to these highly sought-after treatments

Leggi questa versione → originale

giovedì 28 maggio 2026·

morningstar.com

Foundayo and Zepbound now covered for millions of Americans

Foundayo and Zepbound now covered for millions of Americans

giovedì 28 maggio 2026·

cnbc.com

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

giovedì 28 maggio 2026·

qz.com

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

giovedì 28 maggio 2026·

independent.co.uk

CVS expands access to blockbuster weight-drugs in surprise reversal

This move marks a pivotal shift for patients seeking access to these highly sought-after treatments

giovedì 28 maggio 2026·

fiercepharma.com

CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will

giovedì 28 maggio 2026·

endpoints.news

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.

giovedì 28 maggio 2026·

upi.com

CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com